Findings from the trial showed that a significantly greater proportion of patients treated with dupilumab met the primary endpoint achieving significant histological disease remission.
Findings from the trial showed that a significantly greater proportion of patients treated with dupilumab met the primary endpoint achieving significant histological disease remission.
Approval based on Phase 3 EoE KIDS trial showing a greater proportion of children taking Dupixent achieved histological remission compared to placebo Expanded indication marks second disease for.
Dupixent® FDA approved as first and only treatment indicated for children aged 1 year and older with eosinophilic esophagitis Approval based on Phase 3 EoE KIDS trial showing a greater.